Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: Results from a 1-year European observational study

Human Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 284-294

  Kraemer, Susanne ^a   Chartier, Florence ^b   Augendre Ferrante, Béatrice ^b   Psarra, Vassiliki ^c   D'Yachkova, Yulia ^d   Beselin, Anke ^a   Rouillon, Fréderic ^e  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c Psychiatric Hospital of Attiki Dafni   (Greece)

^d Eli Lilly GmbH   (Austria)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

antipsychotic; bipolar disorder; non interventional; schizophrenia

Indexed keywords

OLANZAPINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BIPOLAR DISORDER; CATATONIC SCHIZOPHRENIA; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; EUROPE; FEMALE; FRANCE; FUNCTIONAL STATUS; GERMANY; GREECE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL BEING; RELAPSE; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SUICIDE ATTEMPT; TREATMENT DURATION; UNDIFFERENTIATED SCHIZOPHRENIA; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BODY WEIGHT; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OBSERVATION; OUTPATIENTS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 84861190829     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2224     Document Type: Article

References (35)

1. Amador XF, Strauss DH, Yale SA, Gorman JM,. 1991. Awareness of illness in schizophrenia. Schizophr Bull 17: 113-132.
2. Amador XF, Strauss DH,. 1993. Poor insight in schizophrenia. Psychiatr Q 64: 305-318.
3. Amador XF, Flaum M, Andreasen NC, et al., 1994. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 51: 826-836. (Pubitemid 24313308)
4. Arranz B, San L, Dueñas RM, et al., 2007. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 22 (1): 11-15. (Pubitemid 46178773)
5. Bitter I, Treuer T, Dilbaz N, et al., 2010. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry 11 (7): 894-903.
6. Chawla B, Luxton-Andrew H,. 2008. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol 23 (3): 211-216. (Pubitemid 351577690)
7. Chue P, Jones B, Taylor CC, Dickson R,. 2002. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry 47 (8): 771-774. (Pubitemid 35345722)
8. Ciudad A, Gutiérrez M, Cañas F, et al., 2005. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 29 (6): 944-951. (Pubitemid 41080116)
9. Czekalla J, Wagner T, Schacht A, Kluge M, Kinon B,. 2007. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence 20 (1): 19-27.
10. Dupuy HJ,. 1984. The Psychological General Well-being (PGWB) index. In Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies, Wenger NK, Mattson ME, Furburg CD, Elinson J, (eds). Le Jacq Publishing: New York; 170-183.
11. Endicott J, Spitzer RL, Fleiss JL, Cohen J,. 1976. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
12. Freudenreich O, Goff DC,. 2002. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106 (5): 323-330. (Pubitemid 35176874)
13. Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F, Lépine JP,. 2008. Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France. Eur Psychiatry 23 (7): 491-496.
14. Gonzalez-Pinto A, Vieta E, Reed C, et al., 2011. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania-results of a two year observational study in bipolar disorder (EMBLEM). J Affect Disord 131 (1-3): 320-329.
15. Haro JM, Kamath SA, Ochoa S, et al., 2003. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 416: 16-23.
16. Haro JM, Novick D, Belger M, Jones PB,. 2006a. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatry 21 (1): 41-47. (Pubitemid 43243051)
17. Haro JM, Novick D, Suarez D, et al., 2006b. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 26 (6): 571-578. (Pubitemid 44772733)
18. Haro JM, Suarez D, Novick D, et al., 2007. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus andomized studies results. Eur Neuropsychopharmacol 17 (4): 235-244. (Pubitemid 46164772)
19. Horvath AO, Greenberg LS,. 1989. Development and validation of the Working Alliance Inventory. J Couns Psychol 36: 223-233.
20. Karagianis J, Grossman L, Landry J, et al., 2009. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res 113 (1): 41-48.
21. Kahn R, Fleischhacker W, Boter H, et al., 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097. (Pubitemid 351418005)
22. Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM,. 2008. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. J Clin Psychopharmacol 28 (1): 74-77.
23. Kinon BJ, Hill AL, Liu H, Kollack-Walker S,. 2003. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 6 (2): 97-102. (Pubitemid 36850960)
24. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Asher-Svanum H, Siris SG,. 2006. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 26: 157-162. (Pubitemid 43740339)
25. Lieberman JA, Stroup TS, McEvoy JP, et al., 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (12): 1209-1223. (Pubitemid 41345943)
26. Liu-Seifert H, Houston JP, Hill A,. 2004. Orally Disintegrating Olanzapine and Improvement in Agitation and Attitude toward Compliance in Noncompliant Patients with Schizophrenia. American Psychiatric Association (APA): New York.
27. Liu-Seifert H, Houston JP, Adams DH, Kinon BJ,. 2007. Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia. J Clin Psychopharmacol 27 (4): 392-394. (Pubitemid 47075511)
28. Rihmer Z,. 2005. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2 (1): 48-54.
29. San L, Casillas M, Ciudad A, Gilaberte I,. 2008. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther 14: 203-214.
30. Suarez D, Haro JM,. 2008. Overview of the findings from the European SOHO study. Expert Rev Neurother 8 (6): 873-880. (Pubitemid 351872592)
31. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W,. 1997. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73 (3): 159-171. (Pubitemid 28088172)
32. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial 127 Investigators. 2009. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 166: 476-488.
33. Thompson K, Kulkarni J, Sergejew AA,. 2000. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 42: 241-247. (Pubitemid 30216535)
34. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P,. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168 (6): 603-609.
35. Zeber JE, Copeland LA, Good CB, Fine MJ, Bauer MS, Kilbourne AM,. 2008. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. J Affect Disord 107 (1-3): 53-62. (Pubitemid 351288909)